Erasca (ERAS) Stock Recommended for Purchase by JPMorgan

Erasca, Inc. (ERAS) received an Overweight rating from JPMorgan, which recommends buying the stock at current levels due to anticipated catalysts. H.C. Wainwright also maintains a Buy rating with a price target of $20, following preliminary Phase 1 data for ERAS-0015, which shows potential efficacy in treating non-small cell lung cancer. The data indicates a clear increase in early efficacy, though the safety profile is noted to have some caveats. As a clinical-stage precision oncology company, Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.